Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EB06

Other · developed by Edesa Biotech

Phase 2 Most advanced trial
EDSA Developer
1 Registered trials

What is EB06?

EB06 is an investigational agent given intravenously at a loading dose of 20 mg/kg followed by 10 mg/kg. It is being studied in non-segmental vitiligo.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Dermatology
Developer
Edesa Biotech Inc. (EDSA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
V32759GBS4

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07889492 Phase 2 Non-Segmental Vitiligo (NSV) Recruiting EDSA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-Segmental Vitiligo (NSV)

More from Edesa Biotech

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the EDSA page.

Follow EDSA, the company behind EB06

See EDSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EDSA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.